首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FGF9 |
| Uniprot No | P31371 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 3-208aa |
| 氨基酸序列 | MPLGEVGNYFGVQDAVPFGNVPVLPVDSPVLLSDHLGQSEAGGLPRGPAV TDLDHLKGILRRRQLYCRTGFHLEIFPNGTIQGTRKDHSRFGILEFISIA VGLVSIRGVDSGLYLGMNEKGELYGSEKLTQECVFREQFEENWYNTYSSN LYKHVDTGRRYYVALNKDGTPREGTRTKRHQKFTHFLPRPVDPDKVPELY KDILSQS |
| 预测分子量 | 23 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于FGF9重组蛋白的示例参考文献(注：内容为模拟示例，实际文献请通过学术数据库检索验证)：
---
1. **文献名称**: *Recombinant FGF9 promotes bone regeneration via modulating osteogenesis and angiogenesis*
**作者**: Smith A, et al.
**摘要**: 研究报道了重组FGF9蛋白在大鼠骨缺损模型中的促修复作用，证明其通过激活MAPK信号通路增强成骨细胞分化和血管生成，为骨再生治疗提供新策略。
2. **文献名称**: *Expression and functional characterization of human FGF9 in Escherichia coli*
**作者**: Zhang L, et al.
**摘要**: 本文描述了通过大肠杆菌系统高效表达重组人FGF9蛋白的优化方法，纯化产物经体外细胞实验验证可显著促进软骨细胞增殖，证实其生物活性。
3. **文献名称**: *FGF9 mutation causes carcinogenesis by dysregulating PI3K/AKT pathway*
**作者**: Tanaka K, et al.
**摘要**: 研究利用重组FGF9蛋白处理肺癌细胞，发现其异常表达通过PI3K/AKT信号通路促进肿瘤细胞侵袭和迁移，提示FGF9作为癌症治疗潜在靶点。
4. **文献名称**: *Structural basis of FGF9 homodimerization and receptor binding*
**作者**: Wang Y, et al.
**摘要**: 通过X射线晶体学解析重组FGF9蛋白的三维结构，揭示其同源二聚化模式及与FGFR3受体的结合机制，为设计靶向药物提供结构基础。
---
建议通过 **PubMed**、**Google Scholar** 或 **Web of Science** 输入关键词 "recombinant FGF9 protein" 或 "FGF9 expression and function" 获取真实文献。
**Background of Recombinant FGF9 Protein**
Fibroblast Growth Factor 9 (FGF9) is a member of the FGF family, a group of signaling proteins involved in embryonic development, tissue repair, angiogenesis, and metabolic regulation. FGF9 specifically binds to fibroblast growth factor receptors (FGFR1-3) with heparan sulfate proteoglycans as co-receptors, activating downstream pathways like MAPK, PI3K-AKT, and PLCγ. It plays critical roles in organogenesis, particularly in lung branching morphogenesis, skeletal development, and nervous system regulation. Dysregulation of FGF9 is linked to diseases such as cancer, pulmonary fibrosis, and skeletal dysplasia.
Recombinant FGF9 protein is produced via genetic engineering, typically using bacterial (e.g., *E. coli*) or mammalian expression systems. Bacterial-derived FGF9 is non-glycosylated but retains bioactivity, while mammalian systems yield glycosylated forms closer to native human protein. The recombinant form is purified to homogeneity, ensuring consistency for research and therapeutic applications.
In research, recombinant FGF9 is used to study its roles in tissue regeneration, organoid development, and disease mechanisms. Preclinical studies highlight its potential in treating lung injury, bone defects, or neurodegenerative disorders. However, challenges remain in optimizing delivery methods and minimizing off-target effects. As a tool compound, it also aids in drug screening and understanding FGF signaling crosstalk.
Overall, recombinant FGF9 serves as a vital reagent for exploring FGF biology and advancing translational therapies, though further studies are needed to unlock its full clinical potential.
×
